KTTA
NASDAQ · Biotechnology
Pasithea Therapeutics Corp
$0.80
+0.00 (+0.34%)
Open$0.77
Previous Close$0.80
Day High$0.80
Day Low$0.76
52W High$2.06
52W Low$0.28
Volume—
Avg Volume392.2K
Market Cap19.81M
P/E Ratio—
EPS$-3.47
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,273.4% upside
Current
$0.80
$0.80
Target
$26.92
$26.92
$19.73
$26.92 avg
$29.00
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 325.2K | 3.90M | 3.72M |
| Net Income | -322,998,086 | 467.4K | 601.6K |
| Profit Margin | -14,394.0% | 12.0% | 16.2% |
| EBITDA | -321,846,383 | 1.16M | 1.10M |
| Free Cash Flow | — | 801.3K | 617.9K |
| Rev Growth | — | +18.2% | +4.0% |
| Debt/Equity | — | 0.89 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |